Two-year clinical outcomes of Taiwanese and other Asian ethnicities with atrial fibrillation treated with edoxaban in the ETNA-AF Asia registry.

ABSTRACT:

Background

The non-vitamin K oral anticoagulant (NOAC), edoxaban, is approved for stroke prevention in patients with atrial fibrillation (AF) in many Asian countries. Nonetheless, data on its long-term effectiveness and safety in routine clinical practice are limited in Taiwan.

Methods

The Global ETNA-AF (Edoxaban Treatment in routiNe clinical prActice) registry is an observational study that integrates data of AF patients receiving edoxaban from multiple regional registries. Here, we report the subgroup analysis of two-year outcomes in Taiwan (N = 973) and three Asian countries (South Korea, Hong Kong, Thailand; N = 2326).

Results

Compared with other Asian ethnicities, edoxaban users in Taiwan were older and had lower creatinine clearance levels. The in

SUBMITTER: Wang CC 

PROVIDER: S-EPMC11730714 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature